Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucosaminyl (N-acetyl) transferase 4 (GCNT4) is an enzyme that catalyzes the branching of core 2 O-glycans by transferring GlcNAc from UDP-GlcNAc to the core 1 structure in mucin-type glycoproteins. This function is crucial for proper glycoprotein structure and influences cell–cell interactions, signaling, and tumor suppression. GCNT4 does not have core 4 O-glycan or I-branching enzyme activity. Downregulation or deletion of GCNT4 is associated with increased proliferation and poor prognosis in gastric cancer and other malignancies, indicating its role as a tumor suppressor and biomarker.
For a potential inhibitor or activator, mechanisms would include modulation of glycosylation and subsequent effects on cell proliferation and tumor progression. Tumor-suppressive effects may depend on restoring or enhancing GCNT4 expression/function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucosaminyl (N-acetyl) transferase 4 (GCNT4).